Skip to main content

Day: February 13, 2026

Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. Financial Highlights & Recent DevelopmentsResearch and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines. Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe and Asia.“We continue to see positive momentum in our sales pipeline across our global markets year-to-date in fiscal year 2026. Customers in...

Continue reading

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABILITY-1 clinical data for MDNA11 demonstrates compelling activity in earlier-line expansion cohorts Among expansion cohorts treated with MDNA11 as a 2L or3L systemic treatment or as the next treatment following resistance to checkpoint therapy, MDNA11 demonstrated an objective response rate (“ORR”) of 36% (N=14) in the monotherapy setting and 43% (N=14) when combined with pembrolizumab The ABILITY-1 study has added a new expansion cohort where patients with non-small cell lung cancer (NSCLC) and secondary resistance to checkpoint therapy will be treated with MDNA11 in combination with pembrolizumab, potentially addressing the needs for one...

Continue reading

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

– Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events –– Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 – This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — HELUS PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today reported unaudited financial results for its third quarter ended December 31, 2025, and recent business highlights. “The...

Continue reading

Opus Genetics Announces $25 Million Private Placement

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has entered into a securities purchase agreement for a private placement (the “private placement”) of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock at a price of $3.39 per share. Subject to Opus Genetics stockholder approval of an increase to the authorized shares of common stock sufficient to permit the conversion, each share of Series B Non-Voting Convertible Preferred Stock will automatically convert into one share of common stock for an aggregate of 7,374,632 shares of common stock. The...

Continue reading

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air’s subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination of upfront cash, development and commercial milestones and 19.99% equity ownership in XTL Biopharmaceuticals Phase 1a data from UNO program in solid tumors to be presented at AACR Annual Meeting in April 2026 Conference call at 8:00 a.m. ET today, February 13th    GARDEN CITY, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc....

Continue reading

Loveland Police Department Expands to Department-Wide Deployment of BolaWrap® 150 as Part of Comprehensive Non-Lethal Response Strategy for All Sworn Officers

Agency-wide expansion to a standardized Non-Lethal Response program integrates non-lethal tools, training, and policy across all operational shifts and units. MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or, the “Company”), a global leader in Non-Lethal Response (“NLR”) and public safety technology, today announced the full department-wide deployment of its BolaWrap® 150 device at the Loveland Police Department (“Loveland”) in Colorado, marking a milestone in the department’s transition to standardized, Non-Lethal Response across all sworn officers. The expansion marks a transition from a limited, role-based deployment to the integration of a comprehensive NLR program, with the goal of ensuring all sworn officers have access to BolaWrap as part of the department’s layered approach to de-escalation,...

Continue reading

Prospect Credit REIT Outperforms Stanger Composite Net Asset Value REIT Index in 2025 with 13.14% Annualized Total Return and 9.00% Annualized Distribution Rate

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) — Since closing its first investment on February 6, 2025, through December 31, 2025, Prospect Credit REIT, LLC (“PCRED”), a non-traded real estate credit fund, achieved an annualized total return of 13.14% to investors. PCRED’s annualized return outperformed the 1-year annualized return of the Robert A. Stanger (“Stanger”) Composite NAV REIT Index by 2.01x. The Stanger tracked index, which includes 33 non-traded net asset value real estate investment trusts (“NAV REITs”), returned 6.50% in 2025. Total return is calculated based on total distributions paid to investors for the period plus the change in net asset value attributable to investment operations, divided by ending net asset value and less fees. As of January 2026, PCRED’s current shareholder distribution rate is 9.00% per...

Continue reading

Orrön Energy receives MEUR 1.6 from a previously announced portfolio transaction

Orrön Energy AB (“Orrön Energy”) is pleased to announce that closing has occurred, and a milestone has been achieved, for one of the three solar projects forming part of the portfolio transaction announced in December 2025, triggering payments totalling MEUR 1.6. The project is being developed with an estimated installed capacity of 93 MW and form part of the agreement to sell a portfolio of three Agri-PV projects in Germany with a combined capacity of 234 MW announced in December 2025. Closing for the first project occurred in the beginning of 2026. Shortly thereafter, the first development milestone was achieved through a positive municipality decision, leading to a payment totalling MEUR 1.6, representing 30 percent of the consideration for this project. The total consideration for the 234 MW portfolio sale amounts to up to MEUR 14...

Continue reading

Amid a Positive Outlook, Multiple Crypto Investment Institutions Complete US$60 Million Capital Injection into Jiuzi Holdings, Increasing the Original Planned Amount by 50%; JZXN’s DAT Strategy Enters Scaled Implementation Phase

HANGZHOU, Feb. 13, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (Nasdaq: JZXN) (the “Company”) today announced that it has entered into a definitive Securities Purchase Agreement (SPA) with multiple strategic investment institutions holding leading influence in the fields of crypto treasury management and digital asset allocation. Pursuant to the terms of the agreement, the investors will subscribe to 40,000,000 ordinary shares of the Company at $1.50 per share, for an aggregate transaction value of approximately $60 million, to be injected in the form of equivalent crypto assets. The signing of the agreement was announced on February 12, 2026. All participating investors in this strategic funding round are institutional capital providers specializing in crypto treasury construction, digital asset risk management, and on-chain...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.